ApexOnco Front Page Recent articles 14 March 2025 Sutro calls time on folate At long last luvelta-T is shelved, and Sutro seeks a new focus. 13 March 2025 Ono takes on Takeda in polycythemia vera The Japanese group licenses sapablursen from Ionis for $280m. 20 November 2024 Jefferies 2024 – Cargo tries again with an old idea A CD22-directed Car that has had several owners will next year deliver its most important dataset. 18 November 2024 Scancell’s dilemma delayed The group touts a 72% ORR with SCIB1, but full Scope data have been pushed back into 2025. 18 November 2024 No PRAME encore for Immatics A 5% response rate with IMA402 monotherapy seems unlikely to turn heads. 15 November 2024 The markets stress over Nuvectis NXP800 yields neither severe thrombocytopenia, nor any responses. 14 November 2024 Merck & Co gets in on the bispecific act For $500m the big pharma group secures LaNova's anti-VEGF x PD-1 antibody. 13 November 2024 ASH 2024 preview – more challenges to the BTK order First-gen drugs feature in BCL-2 combos, while Jaypirca and BTK degraders apply extra pressure. Load More Recent Quick take Menarini is late to go early with Orserdu 10 July 2024 Arcus gets anti-CD73 small molecule buy-in 9 July 2024 Ligand taps Apeiron for a new royalty stream 9 July 2024 Gilead mirrors Merck’s endometrial cancer effort 8 July 2024 More Cartitude-4 fears allayed 2 July 2024 Lynparza set for an unexpected EU approval 1 July 2024 Astra reveals more about its TIGIT hand 27 June 2024 End of the road for Imfinzi in adjuvant lung? 25 June 2024 Dethroning Opdivo in bladder cancer falls to Niagara 25 June 2024 ISTH 2024 – Takeda's marker for Genmab and Sanofi 24 June 2024 Load More Most Popular